HUTCHMED CHINA-ADR

HCM is the Nasdaq-listed American Depositary Receipt (ADR) of HUTCHMED (China) Limited, a biopharmaceutical company. Each HCM ADR represents a fraction of the company's ordinary shares, allowing U.S. investors to trade the company's equity on a U.S. exchange. HCM's business focuses on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immune diseases.

HCM operates in the biotechnology and pharmaceutical industry, with a primary focus on oncology and immunology. The company develops small-molecule drugs and monoclonal antibodies, and also markets prescription medicines through its commercial platform. Its activities span drug discovery, clinical development, regulatory approvals, manufacturing, and sales, placing it in the broader healthcare sector.

Investors can review HCM's regulatory filings, such as annual reports and SEC submissions, along with the company's official press releases and pipeline updates. Financial statements, earnings call transcripts, and drug trial results provide further insight. The latest HCM price, volume, and market data displayed on this page can support ongoing research and help track how the stock is reacting to new information.

The 52-week range shows the highest and lowest prices HCM has traded at over the past year, helping investors gauge recent price extremes and volatility. Because this range changes with market activity, the most current figures are shown in the latest HCM data on this page.

For a clinical-stage biopharmaceutical company like HCM, traditional metrics such as the price-to-earnings ratio may be less useful when earnings are limited or negative. Investors often consider price-to-sales, price-to-book, cash position, pipeline value, and comparisons with peer biotechnology companies. Reviewing HCM's financial statements and the valuation data displayed on this page can provide a more complete perspective.

HCM may be available for trading in pre-market and after-hours sessions on U.S. exchanges, depending on liquidity and broker support. These extended sessions typically have lower volume, wider spreads, and greater price volatility than regular trading hours. Availability and hours can vary, so investors should check with their brokerage and review the latest HCM quote before attempting an extended-hours trade.